Clinical Trial Materials

Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News

Symbiosis and Modus Enter Clinical Manufacturing Deal

CMO symbiosis starts producing sevuparin for Modus’ future clinical development in sepsis/septic shock.

10.14.21

Breaking News | Clinical Trial Materials | Clinical Trials | Collaborations & Alliances | Industry News

Enteris Completes Phase 1 Trial of Optimized Peptelligence Oral Leuprolide

Data indicates that the formulation delivers comparable or greater drug levels than subcutaneous or depot injection.

10.05.21

Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News

Clarity and Evergreen Enter Clinical Manufacturing Agreement

Evergreen will manufacture and distribute clinical materials from its Springfield, NJ facility.

10.05.21

Breaking News | Clinical Trial Materials | Industry News

Catalent Opens Clinical Supply Facility in Japan

The 6,000 square-meter site will provide flexible clinical supply services for both local and global pharma and biopharma companies.

10.05.21

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News

Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

Will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine candidate for upcoming clinical trials.

09.21.21

Tevogen Completes Tech Transfer to CDMO BioCentriq

Reaches commercial manufacturing readiness milestone for its investigational COVID-19 therapy TVGN-489.

09.16.21

BioVaxys Reports Progress on Covid-19 Vax Candidate

Bioproduction partner Wuxi Biologics completes synthesis of recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH programs.

09.16.21

Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News

FUJIFILM Diosynth Biotechnologies, NeuExcell Enter Gene Therapy Mfg. Pact

Aims to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke.

09.13.21

APIs | Clinical Trial Materials

Outsourcing the Manufacture of Clinical Trial APIs

What to consider when deciding to partner with a CDMO for manufacturing.

Josh Hoerner, General Manager, Purisys 09.09.21

Clinical Trial Materials | Clinical Trials | Supply Chain

Clinical Trial Kitting

Overcome the challenges to make every sample count.

Claudia Berrón and Arbi Harootoonian, Avantor 09.09.21

Breaking News | cGMP Manufacture | Clinical Trial Materials | Formulation Development | Promotions & Moves

Avomeen Appoints Formulation and Clinical Trial Mfg. Director

Alex Garner will work to further expand and strengthen Avomeen’s formulation and clinical trial manufacturing capabilities to support biopharmaceutical clients.

08.31.21

Virpax Inks MMS019 Manufacturing and Supply Agreement

CDMO Seqens to provide clinical and commercial supply of MMS019.

08.30.21

EOC Pharma and Chime Biologics Extend Partnership

For the CMC development of EOC202, a recombinant LAG-3 protein for cancer immunotherapy.

08.26.21

Breaking News | cGMP Manufacture | Clinical Trial Materials | Formulation Development | Industry News

Quotient Sciences Invests £6.3M in Drug Substance Mfg. Facility

To significantly expand drug substance manufacturing capability at Alnwick, UK facility and create 80 new jobs over the next three years.

08.25.21

Bio News | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News

Beroni Begins Manufacture of Anti-Cancer Drug PENAO

Inks contract manufacturing deal with Aurigene Pharma Services.

08.19.21

Bio News | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News

Cellectar, Evergreen Enter Clinical Manufacturing and Supply Agreement

Evergreen to provide clinical and commercial supply of iopofosine I-131.

08.17.21

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News

Catalent Plans $100M Expansion of Biologics Mfg. Capabilities in Italy

Initial phase includes installation of two 2,000-liter single-use bioreactors and associated investments to support early-and late-phase clinical development.

07.21.21